Pomegra
Vera Health raised a $28.5M Series A led by Threshold Ventures to scale its free clinical AI search engine, now used by more than 800,000 clinicians in 190 countries.
Key Takeaways
- Vera Health raised $28.5M in Series A funding led by Threshold Ventures, announced October 27, 2026.
- Total funding reaches $32M; Mantis VC and SV Angel joined, and Y Combinator and Gradient returned.
- The company reports 800,000+ clinicians in 190 countries and a 12-person team; valuation is undisclosed.
Lead
Vera Health, a San Francisco clinical search engine, announced a $28.5M Series A on October 27, 2026. Threshold Ventures led the round, with new money from Mantis VC and SV Angel. Existing backers Y Combinator and Gradient increased their stakes, bringing total capital raised to $32M.
The company says more than 800,000 clinicians across 190 countries use the product. It has also been the most downloaded clinical mobile app worldwide since June 2026, by its own account. The company did not disclose a valuation or revenue.
What Does Vera Health Actually Do?
Vera Health is a clinical AI search engine that queries more than 60 million peer-reviewed publications, clinical practice guidelines, and FDA and EMA drug labels. It returns answers with claims linked to the underlying research. It also color-codes the strength of the evidence behind each claim, so a clinician can see whether a recommendation rests on a randomized trial or a weaker source.
That grading is the product's main pitch against general-purpose chatbots, which can produce fluent answers with no visible support. Co-founder Taieb Bennani has credited the product's clinician-driven design for its adoption. The company lists compliance with HIPAA and GDPR, holds SOC 2 Type II certification, and says it does not use patient query data to train models.
How Did a 12-Person Team Reach 800,000 Users?
Vera Health grew mainly through peer referrals, with no enterprise marketing spend, according to the company. Its team numbers 12 people. Co-founders Bennani and Maxime Allouch, both MIT graduates and sons of physicians, built the product around daily clinical use. The company reports hundreds of thousands of queries per day.
Adoption is uneven by geography. Vera Health puts its reach at roughly one in four practicing physicians in Spain and Italy, and about one in seven in France. Those are company figures, and they measure users who have signed up rather than verified active physicians. The US figure was not given. That omission matters, because the US is the largest market for clinical software spending.
How Does Vera Health Make Money?
Vera Health makes no money from individual clinicians, because it is permanently free for licensed clinicians and medical trainees. Revenue is meant to come from Vera Spaces, an enterprise offering for hospitals and health systems. The company has not disclosed how many institutions have signed on or what they pay. It has announced a partnership with the American College of Emergency Physicians (ACEP).
A free product with a small team and 800,000 users is a strong top-of-funnel position. It is not yet evidence of a business. The $28.5M round, roughly nine times the capital raised before it, pays for the gap between those two things.
Why Does This Round Matter for Clinical AI?
The round shows investors are still funding clinical search as a category even though the market already has a well-known incumbent in OpenEvidence, along with established reference tools. Vera Health's pitch is differentiation by evidence transparency and international reach rather than a head-on US fight. Threshold partner Emily Melton said the product "starts with the evidence, not just an answer."
The skeptical read is that free clinician tools tend to converge on similar features, and distribution advantages erode when larger competitors match the evidence grading. The favorable read is that international physician networks are hard to copy quickly. Without a disclosed valuation or revenue figure, outsiders cannot tell which read the investors took.
What Will Vera Health Do With the Money?
Vera Health plans to spend the funds on its clinical evidence infrastructure, expansion into additional healthcare markets, and deeper partnerships with medical societies and health systems. It will also grow its team from 12 people.
The measurable milestones are enterprise contracts through Vera Spaces, more society partnerships on the ACEP model, and any traction in the US. A Series B would likely be judged on paid revenue, not download rankings.
Outlook
Vera Health enters its next stage with $32M raised, a lead investor in Threshold Ventures, and user numbers well ahead of its headcount. The unanswered questions are valuation, revenue, and US penetration. Its ability to convert free clinician usage into hospital contracts will decide whether the growth translates into a durable business.
